TheraVasc Inc. is dedicated to reducing the risk, cost and time associated with drug development by focusing on developing repurposed drugs for the unserved vascular disease markets.
TheraVasc's initial product, TV1001 (an oral formulation of sodium nitrite) targets patient populations with poor blood flow to the extremities, such as those with diabetic leg and foot problems or those with peripheral artery disease (PAD). While there are a large and growing number of patients suffering from each of these diseases, there are no effective treatments available.
TV1001 has been shown to selectively promote the re-growth of blood vessels only in ischemic tissues such as those affected in patients with diabetes or by PAD.
Initial JumpStart Investment: December 2009
For more information on TheraVasc, contact: Jerry Frantz